Prospective study of identification of early-stage breast cancer with a minimal risk of recurrence by the Breast Cancer Index

A prospective study assessed the prognostic ability of an adjusted Breast Cancer Index (BCI) model to identify patients at minimal risk (<5%) of 10-year distant recurrence (DR) who are unlikely to benefit from adjuvant endocrine therapy.The study included postmenopausal patients wirh early-stage, HR-positive N0 breast cancer who underwent surgery alone or received surgery plus adjuvant tamoxifen. The adjusted BCI model stratified patients into four prognostic risk groups. The BCI risk scores provided additional independent information over standard prognostic factors. The authors conclude that the adjusted BCI model identified women with early-stage, HR-positive, N0 breast cancerat a minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.